NASDAQ:NVAXNovavax Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.90 -1.20 (-7.45 %) (As of 04/8/2020 02:06 AM ET) Add Compare Share Today's Range$14.38Now: $14.90▼$16.0050-Day Range$6.91MA: $11.20▼$16.1052-Week Range$3.54Now: $14.90▼$17.71Volume4.70 million shsAverage Volume8.21 million shsMarket Capitalization$767.77 millionP/E RatioN/ADividend YieldN/ABeta0.53 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingNovavax has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.86, Novavax has a potential upside of 26.6% from its current price of $14.90.Amount of Analyst CoverageNovavax has only been the subject of 4 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesNovavax has received 767 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovavax has received 467 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovavax has received 62.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote “Outperform” if you believe NVAX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovavax does not currently pay a dividend.Dividend GrowthNovavax does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novavax insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,825.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of Novavax is held by insiders.Percentage Held by InstitutionsOnly 20.68% of the stock of Novavax is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Novavax are expected to decrease by -8.10% in the coming year, from ($2.47) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novavax is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novavax is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.91 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NVAX Previous Symbol CUSIP67000210 CIK1000694 Webhttp://www.novavax.com/ Phone240-268-2000Debt Debt-to-Equity RatioN/A Current Ratio3.77 Quick Ratio3.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.66 million Price / Sales41.15 Cash FlowN/A Price / Cash FlowN/A Book Value($5.75) per share Price / Book-2.59Profitability EPS (Most Recent Fiscal Year)($5.80) Net Income$-132,690,000.00 Net Margins-711.04% Return on EquityN/A Return on Assets-74.72%Miscellaneous Employees373 Outstanding Shares51,528,000Market Cap$767.77 million Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive NVAX News and Ratings via Email Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NVAX Rates by TradingView Novavax (NASDAQ:NVAX) Frequently Asked Questions How has Novavax's stock been impacted by COVID-19 (Coronavirus)? Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVAX shares have increased by 41.8% and is now trading at $14.90. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Novavax? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novavax. When is Novavax's next earnings date? Novavax is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Novavax. How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings results on Wednesday, March, 11th. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.06) by $0.07. The biopharmaceutical company earned $8.82 million during the quarter, compared to analyst estimates of $3.99 million. View Novavax's earnings history. When did Novavax's stock split? How did Novavax's stock split work? Novavax shares reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split. What price target have analysts set for NVAX? 7 brokerages have issued 12 month price objectives for Novavax's shares. Their forecasts range from $7.00 to $24.00. On average, they expect Novavax's stock price to reach $18.86 in the next twelve months. This suggests a possible upside of 26.6% from the stock's current price. View analysts' price targets for Novavax. Has Novavax been receiving favorable news coverage? Press coverage about NVAX stock has trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novavax earned a news impact score of -3.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutNovavax. Who are some of Novavax's key competitors? Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Gilead Sciences (GILD), Cara Therapeutics (CARA), Trevena (TRVN), Inovio Pharmaceuticals (INO) and Opko Health (OPK). Who are Novavax's key executives? Novavax's management team includes the following people: Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)Dr. Gregory M. Glenn, Pres of R&D (Age 65)Ms. Erika S. Trahan, Sr. Mang. of Investor & PR What is Novavax's stock symbol? Novavax trades on the NASDAQ under the ticker symbol "NVAX." How do I buy shares of Novavax? Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Novavax's stock price today? One share of NVAX stock can currently be purchased for approximately $14.90. How big of a company is Novavax? Novavax has a market capitalization of $767.77 million and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe. View additional information about Novavax. What is Novavax's official website? The official website for Novavax is http://www.novavax.com/. How can I contact Novavax? Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: What is the Difference Between Common Shares and Convertible Shares?
